Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Common Equity: 2024-2025

Historic Common Equity for Pharming Group N.V (PHAR) over the last 2 years, with Sep 2025 value amounting to -$4.

  • Pharming Group N.V's Common Equity rose 81.82% to -$4 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4, marking a year-over-year increase of 81.82%. This contributed to the annual value of $221.1 million for FY2024, which is N/A change from last year.
  • Per Pharming Group N.V's latest filing, its Common Equity stood at -$4 for Q3 2025, which was up 73.33% from -$15 recorded in Q2 2025.
  • In the past 5 years, Pharming Group N.V's Common Equity registered a high of $221.1 million during Q4 2024, and its lowest value of -$22 during Q3 2024.
  • Its 2-year average for Common Equity is $31.6 million, with a median of -$4 in 2025.
  • Examining YoY changes over the last 5 years, Pharming Group N.V's Common Equity showed a top increase of 81.82% in 2025 and a maximum decrease of 15.79% in 2025.
  • Over the past 2 years, Pharming Group N.V's Common Equity (Quarterly) stood at $221.1 million in 2024, then skyrocketed by 81.82% to -$4 in 2025.
  • Its Common Equity was -$4 in Q3 2025, compared to -$15 in Q2 2025 and -$0.02 in Q1 2025.